Merck Announces First-Quarter 2023 Dividend

Rhea-AI Summary

Merck (NYSE: MRK) announced a quarterly dividend of $0.73 per share for Q1 2023, to be paid on Jan. 9, 2023. This payment is for shareholders of record as of Dec. 15, 2022. Merck aims to leverage leading-edge science to improve lives globally and remains committed to research and development in the biopharmaceutical sector. The company emphasizes its dedication to sustainability and a diverse workforce, striving for a healthy future for all communities.

Positive

• Quarterly dividend of $0.73 per share enhances income for shareholders.
• Merck's commitment to leading-edge science strengthens investor confidence.

Negative

• None.

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.73 per share of the company’s common stock for the first quarter of 2023. Payment will be made on Jan. 9, 2023, to shareholders of record at the close of business on Dec.15, 2022.

About Merck

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005797/en/

Media:

Michael Levey

(215) 872-1462

Johanna Herrmann

(617) 216-6029

Investors:

Peter Dannenbaum

(908) 740-1037

Steven Graziano

(908) 740-6582

Source: Merck & Co., Inc.

FAQ

What is the dividend amount declared by Merck for Q1 2023?

Merck declared a quarterly dividend of $0.73 per share for Q1 2023.

When will Merck's dividend be paid?

The dividend will be paid on January 9, 2023.

What is the record date for Merck's Q1 2023 dividend?

The record date for the dividend is December 15, 2022.

How often does Merck pay dividends?

Merck typically pays dividends on a quarterly basis.